Drug intelligence / Profile preview

BAT1006

Development stage: Phase 1
Lead developer: Bio-Thera Solutions
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BAT1006 is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 (HER2). It is designed with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) to improve anti-tumor activity. The drug is being developed for the treatment of HER2-positive locally advanced or metastatic solid tumors, including breast cancer. Clinical development includes dose escalation and expansion studies, as well as combination therapy with other HER2-based treatments such as antibody-drug conjugates. BAT1006 is being developed by Bio-Thera Solutions[2][3][4][6].

Targets

HER2 ECD II (Human epidermal growth factor receptor 2 domain II)

Beyond the preview

Go deeper on BAT1006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAT1006.

Explore the full profile